Hicham Skali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5090733/publications.pdf

Version: 2024-02-01

44069 37204 9,785 144 48 96 citations h-index g-index papers 158 158 158 11845 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients. Circulation, 2005, 112, 3738-3744.	1.6	678
2	Cardiac Positron Emission Tomography Enhances Prognostic Assessments of Patients With Suspected Cardiac Sarcoidosis. Journal of the American College of Cardiology, 2014, 63, 329-336.	2.8	572
3	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation, 2007, 116, 1482-1487.	1.6	528
4	Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis. Journal of Clinical Oncology, 2014, 32, 2380-2385.	1.6	501
5	Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. Journal of the American College of Cardiology, 2002, 39, 1450-1455.	2.8	393
6	Body Mass Index and Prognosis in Patients With Chronic Heart Failure. Circulation, 2007, 116, 627-636.	1.6	328
7	Two-Dimensional Assessment of Right Ventricular Function: An Echocardiographic?MRI Correlative Study. Echocardiography, 2007, 24, 452-456.	0.9	327
8	Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction. Circulation, 2005, 111, 3411-3419.	1.6	251
9	Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. Journal of Nuclear Cardiology, 2014, 21, 166-174.	2.1	242
10	Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients. Circulation, 2004, 110, 2180-2183.	1.6	241
11	Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction. JACC: Cardiovascular Imaging, 2008, 1, 582-591.	5. 3	227
12	Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. Circulation, 2004, 110, 1572-1578.	1.6	201
13	Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study). American Journal of Cardiology, 2008, 101, 607-612.	1.6	197
14	Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. Circulation, 2010, 122, 597-602.	1.6	195
15	Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2018, 11, e007030.	2.6	187
16	Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction. Circulation, 2004, 110, 3667-3673.	1.6	185
17	Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. Journal of Nuclear Cardiology, 2017, 24, 86-99.	2.1	170
18	Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction. Journal of the American Society of Nephrology: JASN, 2006, 17, 2886-2891.	6.1	167

#	Article	IF	Citations
19	Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. American Heart Journal, 2011, 162, 548-554.	2.7	150
20	Prognostic Significance of Troponin Elevation and Right Ventricular Enlargement in Acute Pulmonary Embolism. American Journal of Cardiology, 2005, 96, 303-305.	1.6	147
21	Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 1785-1795.	2.8	146
22	Temporal Trends in the Population Attributable Risk for Cardiovascular Disease. Circulation, 2014, 130, 820-828.	1.6	135
23	Impact of Diabetes on Mortality in Patients With Myocardial Infarction and Left Ventricular Dysfunction. Archives of Internal Medicine, 2004, 164, 2273.	3.8	134
24	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. European Heart Journal, 2011, 32, 1227-1234.	2.2	130
25	18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis. Current Cardiology Reports, 2013, 15, 1.	2.9	124
26	Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. Journal of Nuclear Cardiology, 2018, 25, 1136-1146.	2.1	121
27	Rationale and Design of a Multicenter Echocardiographic Study to Assess the Relationship Between Cardiac Structure and Function and Heart Failure Risk in a Biracial Cohort of Community-Dwelling Elderly Persons. Circulation: Cardiovascular Imaging, 2014, 7, 173-181.	2.6	117
28	Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. Journal of the American Heart Association, 2017, 6, .	3.7	98
29	Ventricular Remodeling Does Not Accompany the Development of Heart Failure in Diabetic Patients After Myocardial Infarction. Circulation, 2002, 106, 1251-1255.	1.6	94
30	Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa. Circulation, 2011, 124, 2903-2908.	1.6	89
31	Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. European Heart Journal, 2007, 28, 326-333.	2.2	88
32	Heart Failure and Midrange Ejection Fraction. Circulation: Heart Failure, 2016, 9, e002826.	3.9	84
33	Computed tomography-fluoroscopy overlay evaluation during catheter ablation of left atrial arrhythmia. Europace, 2008, 10, 931-938.	1.7	79
34	Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 2015-2021.	2.8	71
35	Mortality Rates in Trials of Subjects With Type 2 Diabetes. Journal of the American Heart Association, 2012, 1, 8-15.	3.7	71
36	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney International, 2019, 95, 973-982.	5.2	70

3

#	Article	IF	CITATIONS
37	Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease. Circulation: Heart Failure, 2015, 8, 448-454.	3.9	68
38	Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and Â-galactosidase A activity. European Heart Journal, 2010, 31, 1088-1097.	2.2	66
39	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. European Heart Journal, 2015, 36, 669-675.	2.2	62
40	Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: <scp>MADITâ€CRT</scp> . European Journal of Heart Failure, 2014, 16, 560-565.	7.1	60
41	Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage. Kidney International, 2018, 93, 501-509.	5.2	59
42	Cardiovascular Dysfunction and Frailty Among Older Adults in the Community: The ARIC Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw199.	3.6	58
43	Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI. Journal of Nuclear Cardiology, 2020, 27, 1022-1029.	2.1	56
44	Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2019, 12, e008975.	2.6	54
45	Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment. Circulation, 2020, 141, 21-33.	1.6	54
46	Yield of Downstream Tests After Exercise Treadmill Testing. Journal of the American College of Cardiology, 2014, 63, 1264-1274.	2.8	51
47	Absolute Quantitation of Cardiac ^{99m} Tc-Pyrophosphate Using Cadmium-Zinc-Telluride–Based SPECT/CT. Journal of Nuclear Medicine, 2021, 62, 716-722.	5.0	51
48	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (<scp>VALIANT</scp>). European Journal of Heart Failure, 2015, 17, 301-312.	7.1	50
49	Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm, 2006, 3, 313-316.	0.7	49
50	18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis. Current Cardiology Reports, 2013, 15, 352.	2.9	47
51	Comparison of Regional Versus Global Assessment of Left Ventricular Function in Patients with Left Ventricular Dysfunction, Heart Failure, or Both After Myocardial Infarction: The Valsartan in Acute Myocardial Infarction Echocardiographic Study. Journal of the American Society of Echocardiography, 2006, 19, 1462-1465.	2.8	46
52	Heart Failure Risk Across the SpectrumÂofÂAnkle-Brachial Index. JACC: Heart Failure, 2014, 2, 447-454.	4.1	46
53	Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care, 2016, 39, 677-685.	8.6	46
54	Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. American Heart Journal, 2005, 150, 257-262.	2.7	45

#	Article	IF	Citations
55	Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT. Radiology, 2019, 291, 330-337.	7.3	45
56	Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study. Journal of the American Heart Association, 2015, 4, .	3.7	41
57	Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. JAMA Cardiology, 2018, 3, 200.	6.1	41
58	Detection of Obstructive Coronary Artery Disease Using Regadenoson Stress and ⁸² Rb PET/CT Myocardial Perfusion Imaging. Journal of Nuclear Medicine, 2013, 54, 1748-1754.	5.0	40
59	Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. European Heart Journal, 2016, 37, 466-472.	2.2	40
60	Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. American Heart Journal, 2011, 162, 685-691.	2.7	39
61	Approaches to Reducing Radiation Dose from Radionuclide Myocardial Perfusion Imaging. Journal of Nuclear Medicine, 2015, 56, 592-599.	5.0	39
62	Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. European Journal of Heart Failure, 2012, 14, 185-192.	7.1	38
63	Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. JAMA Cardiology, 2019, 4, 997.	6.1	38
64	Association of Left Atrial Structure and Function With HeartÂFailure in OlderÂAdults. Journal of the American College of Cardiology, 2022, 79, 1549-1561.	2.8	38
65	Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials. Circulation, 2006, 114, 2298-2303.	1.6	34
66	Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study. Journal of the American Heart Association, 2017, 6, .	3.7	32
67	Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. Heart, 2019, 105, 34-41.	2.9	32
68	Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test. Journal of Nuclear Cardiology, 2012, 19, 970-978.	2.1	31
69	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Research and Care, 2014, 2, e000011.	2.8	31
70	Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT. Journal of Cardiovascular Translational Research, 2016, 9, 421-428.	2.4	30
71	High-risk myocardial infarction in the young: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal, 2008, 155, 706-711.	2.7	29
72	Guidance and best practices for reestablishment of non-emergent care in nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An information statement from ASNC, IAEA, and SNMMI. Journal of Nuclear Cardiology, 2020, 27, 1855-1862.	2.1	28

#	Article	IF	Citations
73	Marantic Endocarditis and Disseminated Intravascular Coagulation With Systemic Emboli in Presentation of Pancreatic Cancer. Journal of Clinical Oncology, 2008, 26, 1383-1385.	1.6	27
74	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. Journal of Heart and Lung Transplantation, 2014, 33, 372-381.	0.6	26
75	Racial Disparities in Risks of Stroke. New England Journal of Medicine, 2017, 376, 2089-2090.	27.0	24
76	Widening Racial Differences in Risks for Coronary Heart Disease. Circulation, 2018, 137, 1195-1197.	1.6	24
77	Race- and Gender-Based Differences inÂCardiac Structure and Function andÂRisk of HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 355-368.	2.8	24
78	Sex and Race Differences in N-Terminal Pro–B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community. JAMA Cardiology, 2022, 7, 623.	6.1	23
79	Prognostic use of echocardiography 1 year after a myocardial infarction. American Heart Journal, 2005, 150, 743-749.	2.7	22
80	Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. Heart Rhythm, 2007, 4, 308-313.	0.7	21
81	Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial) Tj ETQq1 Diseases, 2013, 61, 238-246.	1 0.7843 1.9	14 rgBT /0 21
82	18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Current Cardiology Reports, 2013, 15, 352.	2.9	21
83	Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction. JAMA Network Open, 2019, 2, e195321.	5.9	20
84	Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. Hypertension, 2020, 76, 808-818.	2.7	20
85	Diabetes and Progression of HeartÂFailure. Journal of the American College of Cardiology, 2022, 79, 2285-2293.	2.8	19
86	Resting Heart Rate and Chronotropic Response to Exercise: Prognostic Implications in Heart Failure Across the Left Ventricular Ejection Fraction Spectrum. Journal of Cardiac Failure, 2018, 24, 753-762.	1.7	18
87	Influence of Proteinuria on Cardiovascular Risk and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction. Journal of the American College of Cardiology, 2006, 47, 1725-1727.	2.8	17
88	Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. American Heart Journal, 2011, 161, 1156-1162.	2.7	17
89	Association of High-Sensitivity Cardiac Troponin T and Natriuretic Peptide With Incident ESRD: The Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Kidney Diseases, 2015, 65, 550-558.	1.9	16
90	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. European Journal of Heart Failure, 2020, 22, 1133-1143.	7.1	16

#	Article	IF	Citations
91	Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. JAMA Cardiology, 2021, 6, 509.	6.1	16
92	Anatomical distribution of traumatic pneumothoraces on chest computed tomography: implications for ultrasound screening in the ED. American Journal of Emergency Medicine, 2012, 30, 1025-1031.	1.6	15
93	Prognostic value of coronary CTA vs. exercise treadmill testing: results from the Partners registry. European Heart Journal Cardiovascular Imaging, 2015, 16, 1338-1346.	1.2	15
94	Risk Assessment in Patients with Depressed Left Ventricular Function After Myocardial Infarction Using the Myocardial Performance Index–Survival and Ventricular Enlargement (SAVE) Experience. Journal of the American Society of Echocardiography, 2006, 19, 28-33.	2.8	14
95	Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI. Journal of Nuclear Medicine, 2020, , jnumed.120.246686.	5.0	14
96	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemiaâ€"the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). Journal of Human Hypertension, 2016, 30, 46-52.	2.2	13
97	Association of pulmonary hypertension and right ventricular function with exercise capacity in heart failure. ESC Heart Failure, 2020, 7, 1635-1644.	3.1	13
98	Guidance and Best Practices for Reestablishment of Non-Emergent Care in Nuclear Cardiology Laboratories During the Coronavirus Disease 2019 (COVID-19) Pandemic: An Information Statement from ASNC, IAEA, and SNMMI. Journal of Nuclear Medicine Technology, 2021, 49, 13-18.	0.8	12
99	Differential Influence of Distinct Components of Increased Blood Pressure on Cardiovascular Outcomes. Hypertension, 2013, 62, 492-498.	2.7	11
100	Reducing radiation dose from myocardial perfusion imaging in subjects with complex congenital heart disease. Journal of Nuclear Cardiology, 2021, 28, 1395-1408.	2.1	9
101	Appropriateness of inpatient stress testing: Implications for development of clinical decision support mechanisms and future criteria. Journal of Nuclear Cardiology, 2021, 28, 1988-1997.	2.1	9
102	Role of Exercise Treadmill Testing inÂtheÂAssessment of Coronary MicrovascularÂDisease. JACC: Cardiovascular Imaging, 2022, 15, 312-321.	5.3	9
103	Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late Life. Journal of the American Heart Association, 2021, 10, e020094.	3.7	9
104	Novel techniques for assessment of left ventricular systolic function. Heart Failure Reviews, 2011, 16, 327-337.	3.9	8
105	Coronary vasomotor dysfunction portends worse outcomes in patients with breast cancer. Journal of Nuclear Cardiology, 2022, 29, 3072-3081.	2.1	8
106	Guidance and Best Practices for Nuclear Cardiology Laboratories During the COVID-19 Pandemic. Circulation: Cardiovascular Imaging, 2020, 13, e011761.	2.6	7
107	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis. PLoS Medicine, 2020, 17, e1003361.	8.4	7
108	Are we asking too much of our trials?. American Heart Journal, 2002, 143, 1-3.	2.7	6

#	Article	IF	CITATIONS
109	PRAISE (Prospective Randomized Amlodipine Survival Evaluation) andÂCriticism â^—. JACC: Heart Failure, 2013, 1, 315-317.	4.1	6
110	Update on guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: Emphasis on transition to chronic endemic state. An information statement from ASNC, IAEA, and SNMMI. Journal of Nuclear Cardiology, 2022, 29, 2013-2018.	2.1	6
111	Review: Prospects for ARB in the next five years. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, 215-218.	1.7	5
112	Risk Stratification of Resistant Hypertension in Chronic KidneyÂDisease. Journal of the American College of Cardiology, 2013, 61, 2468-2470.	2.8	5
113	Stress Myocardial Perfusion PET Provides Incremental Risk Prediction in Patients with and Patients without Diabetes. Radiology: Cardiothoracic Imaging, 2019, 1, e180018.	2.5	5
114	Cardiac Structure and Function and Diabetesâ€Related Risk of Death or Heart Failure in Older Adults. Journal of the American Heart Association, 2022, 11, e022308.	3.7	5
115	Impact of coronary artery calcium testing on patient management. Journal of Cardiovascular Computed Tomography, 2022, 16, 303-308.	1.3	5
116	The COVID-19 pandemic and nuclear cardiology: An opportunity to grow stronger?. Journal of Nuclear Cardiology, 2021, 28, 336-337.	2.1	4
117	High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study. Clinical Chemistry, 2021, 67, 298-307.	3.2	4
118	Comparison of the Use of Downstream Tests After Exercise Treadmill Testing by Cardiologists Versus Noncardiologists. American Journal of Cardiology, 2014, 114, 305-311.	1.6	2
119	Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial. Kidney360, 2020, 1, 1380-1389.	2.1	2
120	Association of Pulmonary Function With Lateâ€Life Cardiac Function and Heart Failure Risk: The ARIC Study. Journal of the American Heart Association, 2022, 11, .	3.7	2
121	Correlative imaging of spontaneous coronary artery dissection. Journal of Nuclear Cardiology, 2012, 19, 625-629.	2.1	1
122	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal, 2016, 1, 93-100.	5.5	1
123	EXERCISE TREADMILL TESTING HAS LOW UTILITY IN THE EVALUATION OF CORONARY MICROVASCULAR DISEASE. Journal of the American College of Cardiology, 2019, 73, 1568.	2.8	1
124	CAD is a Risk Factor for Heart Failure with Preserved Ejection Fraction: The ARIC Study. Journal of Cardiac Failure, 2019, 25, S93.	1.7	1
125	Weight Loss and Its Predictors During Participation in Cardiac Rehabilitation. American Journal of Cardiology, 2022, 178, 18-25.	1.6	1
126	Assessment of Intrinsic Cardiac Function, Myocardial Blood Flow and Metabolism in Patients Supported on Mechanical Circulatory Assist Devices. Journal of Cardiac Failure, 2011, 17, S37.	1.7	0

#	Article	lF	Citations
127	Reducing Infarct Size With EPO in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Kidney Diseases, 2011, 58, 876-878.	1.9	О
128	Response to Letter Regarding Article, $\hat{a} \in \mathbb{C}$ Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both $\hat{a} \in \mathbb{C}$ Circulation, 2011, 123, .	1.6	0
129	Response to Letter Regarding Article, "Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study― Circulation: Heart Failure, 2015, 8, 1010-1010.	3.9	0
130	Cardiac Troponin. Hospital Medicine Clinics, 2016, 5, 492-506.	0.2	O
131	Persistently High Cardiac Troponin T with a Negative Cardiac Workup. Clinical Chemistry, 2016, 62, 896-897.	3.2	0
132	ASSOCIATION OF RIGHT VENTRICULAR DYSFUNCTION WITH FUNCTIONAL CAPACITY AND RESPIRATORY EFFICIENCY IN HEART FAILURE AND THE IMPACT OF LVEF. Journal of the American College of Cardiology, 2019, 73, 885.	2.8	0
133	SEX AND RACE DIFFERENCES IN CIRCULATING LEVELS OF NATRIURETIC PEPTIDE CONCENTRATIONS AND THE ASSOCIATION WITH INCIDENT HEART FAILURE IN THE COMMUNITY: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY. Journal of the American College of Cardiology, 2019, 73, 911.	2.8	0
134	CMR AND ECHOCARDIOGRAPHIC ASSESSMENT OF LEFT VENTRICULAR STRAIN IN TRANSTHYRETIN CARDIAC AMYLOIDOSIS. Journal of the American College of Cardiology, 2019, 73, 1559.	2.8	0
135	Abstract P055: Diabetes, Early Heart Failures Stages (A & B), And Progression To Overt Heart Failure In Older Adults: The Atherosclerosis Risk In Communities Study. Circulation, 2021, 143, .	1.6	0
136	Abstract 15318 : Longitudinal Changes in Pulmonary Pressure in Late Life: The Atherosclerosis Risk in Communities Study. Circulation, 2020, 142, .	1.6	0
137	Abstract 15448: Association of Kidney Dysfunction and Damage to Incident Heart Failure With Reduced and Preserved Ejection Fraction in Older, Community-dwelling Adults: The Atherosclerosis Risk in Communities Study. Circulation, 2020, 142, .	1.6	0
138	Abstract P088: Valvular Heart Disease Stages And Biomarkers Of Myocardial Stress And Injury Among Older Adults In The Community: The Atherosclerosis Risk In Communities Study. Circulation, 2022, 145,	1.6	0
139	Abstract 10392: Association of Frailty with Incident Heart Failure with Preserved and Reduced Ejection Fraction in Late Life: The Aric Study. Circulation, 2021, 144, .	1.6	0
140	Title is missing!. , 2020, 17, e1003361.		0
141	Title is missing!. , 2020, 17, e1003361.		0
142	Title is missing!. , 2020, 17, e1003361.		0
143	Title is missing!. , 2020, 17, e1003361.		0
144	Title is missing!. , 2020, 17, e1003361.		0